Chemistry:TDIQ
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C10H11NO2 |
| Molar mass | 177.199 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
TDIQ (also known as 6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline or MDTHIQ) is a drug used in scientific research, which has anxiolytic and anorectic effects in animals.[1][2] It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine,[3] but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects.[4] It is thought these effects are mediated via a partial agonist action at Alpha-2 adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.[5]
See also
- MDAI
- MDAT
- Norsalsolinol
- Tetrahydroisoquinoline
- C10H11NO2
References
- ↑ "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of "snacks" in mice". Pharmacology Biochemistry and Behavior 84 (1): 74–83. May 2006. doi:10.1016/j.pbb.2006.04.007. PMID 16750261.
- ↑ "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice". Pharmacology Biochemistry and Behavior 84 (1): 62–73. May 2006. doi:10.1016/j.pbb.2006.04.006. PMID 16750844.
- ↑ "The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine". Pharmacology Biochemistry and Behavior 71 (1–2): 205–13. 2002. doi:10.1016/S0091-3057(01)00666-9. PMID 11812524.
- ↑ "Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline". Pharmacology Biochemistry and Behavior 72 (1–2): 379–87. May 2002. doi:10.1016/S0091-3057(01)00768-7. PMID 11900809.
- ↑ Young R (2007). "TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-gisoquinoline): discovery, pharmacological effects, and therapeutic potential"]. CNS Drug Reviews 13 (4): 405–22. doi:10.1111/j.1527-3458.2007.00022.x. PMID 18078426.
 |  |
